InMed Pharmaceuticals Inc. (INM)
| Market Cap | 10.34M +113.1% |
| Revenue (ttm) | n/a |
| Net Income | -13.60M |
| EPS | -29.93 |
| Shares Out | 664.41K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,154 |
| Open | 13.71 |
| Previous Close | 13.21 |
| Day's Range | 13.70 - 16.44 |
| 52-Week Range | 5.75 - 23.30 |
| Beta | 0.99 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About INM
InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer’s disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Financial Performance
Financial StatementsNews
3 Stocks with More Than 40% Upside and Recent Buy Ratings from Analysts
MongoDB ($MDB), InMed Pharmaceuticals ($INM), and City Therapeutics, Inc. ($CTY) are three stocks that could offer more than 40% upside based on consensus targets. Analysts have recently initiated Buy...
InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics
Shares expected to trade on Nasdaq under the ticker symbol "MTRI" commencing November 9, 2026 VANCOUVER, BC, Nov. 6, 2026 /PRNewswire/ -- InMed Pharmaceuticals Inc. (which has changed its name to Ment...
InMed expects to start trading as Mentari Therapeutics on November 9
InMed Pharmaceuticals (INM) announced that, subject to the satisfaction or waiver of the remaining closing conditions under the agreement and plan of merger and reorganization dated May 19, the compan...
InMed Announces Expected Closing of Merger and Commencement of Trading on Nasdaq Under the Name "Mentari Therapeutics, Inc." and Ticker Symbol "MTRI"
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (now Mentari Therapeutics, Inc.) (the "Company"), a pharmaceutical company focused on develo...
InMed Pharmaceuticals Inc trading resumes
10:01 EST InMed Pharmaceuticals (INM) Inc trading resumes
InMed Pharmaceuticals Inc trading halted, volatility trading pause
09:51 EST InMed Pharmaceuticals (INM) Inc trading halted, volatility trading pause
InMed Pharmaceuticals Inc trading halted, news pending
19:50 EST InMed Pharmaceuticals (INM) Inc trading halted, news pending
InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (now Mentari Therapeutics, Inc.) (the "Company"), a pharmaceutical company focused on develo...
InMed Pharmaceuticals reports Q1 EPS (42c) vs (44c) last year
“We are approaching an important milestone in our proposed merger with Mentari Therapeutics, with our annual general and special meeting scheduled for November 4, 2026,” commented Eric A. Adams, InMed...
InMed Reports First Quarter Fiscal 2027 Financial Results and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - November 3, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pro...
InMed Pharmaceuticals Quarterly report: Q1 2027
InMed Pharmaceuticals has published its Q1 2027 quarterly earnings report on November 3, 2026.
InMed Pharmaceuticals Earnings release: Q1 2027
InMed Pharmaceuticals released its Q1 2027 earnings on November 3, 2026, summarizing the period's financial results.
InMed Announces Share Consolidation in Connection with Proposed Merger
Vancouver, British Columbia--(Newsfile Corp. - November 2, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pro...
InMed Announces CVR Distribution Record Date in Connection with Proposed Merger
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pro...
InMed receives Nasdaq notification from listing qualifications department
InMed Pharmaceuticals (INM) announces that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market, notifying the company that the shareholders’ equity of $1.075...
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of p...
InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...
InMed Pharmaceuticals Annual report: Q4 2026
InMed Pharmaceuticals has published its Q4 2026 annual report on September 9, 2026.
InMed Pharmaceuticals Earnings release: Q4 2026
InMed Pharmaceuticals released its Q4 2026 earnings on September 9, 2026, summarizing the period's financial results.
Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
WALTHAM, Mass., July 22, 2026 /PRNewswire/ -- Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $200 millio...
InMed Pharmaceuticals amends merger pact with Mentari Therapeutics
InMed Pharmaceuticals (INM) announced that it has entered into an amendment to the previously announced definitive merger agreement for an all-stock transaction with Mentari Therapeutics, a privately-...
InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4
Vancouver, British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") today announced that it has entered in...
InMed regains compliance with Nasdaq continued listing requirements
InMed Pharmaceuticals (INM) announced that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on June 3, 2026 informing the company that it…
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing ...
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM)
BALA CYNWYD, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of InMed Pharmaceuticals, Inc. (“InM...